Summary
Tarsus Pharmaceuticals (TARS) has shown strong technical indicators, including a 48.35% gain since the Trend Seeker buy signal on 9/4 and 173.43% gain in the last year.
The company focuses on novel eye care therapeutics, with its lead product XDEMVY targeting blepharitis caused by Demodex mites and other promising candidates in development.
Fundamental factors are robust, with a market cap of $2.12 billion and expected revenue growth of 898.49% this year and 78.44% next year.
-
Wall Street analysts are bullish with 8 strong buy ratings, although MorningStar considers the stock 25% overvalued; investors should follow disciplined risk
management.
The Chart of the Day belongs to the eye care therapeutics company Tarsus Pharmaceuticals TARS. I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 9/4 the stock gained 48.35%.
TARS Price vs Daily Moving Averages:
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart Technical Indicators:
- 100% technical buy signals
- 176.77+ Weighted Alpha
- 173.43% gain in the last year
- Trend Seeker buy signal
- 1.04 - 60 month Beta
- Above its 20, 50 and 100 day moving averages
- 4 new highs and up 5.57% in the last month
- Relative Strength Index 66.86%
- Technical support level at $54.49
- Recently traded at $55.37 with 50 day moving average of $48.35
Fundamental Factors:
- Market Cap $2.12 billion
- Revenue expected to grow 898.49% his year and another 78.44% next year
- Earnings estimated to increase 25.82% this year and an additional 41.83% next year
Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:
- Wall street analysts issued 8 strong buy and 1 hold opinion on the stock
- Their price targets are between $41 and $84
- CFRA's MarketScope has a buy based on quant factors
- MorningStar thinks the stock is 25% over valued
- 2,000 investors monitor the stock on Seeking Alpha
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
